Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

dry powder inhaler

A technology of dry powder inhaler and inhaler, which is applied in the direction of inhaler, powder delivery, drug equipment, etc., and can solve the problems of lack of equipment durability, lack of practicability, manufacturing cost, poor depolymerization, etc.

Active Publication Date: 2022-05-27
MANNKIND CORP
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is still room for improvement due to lack of practicality and / or manufacturing cost
Some long-standing problems with prior art inhalers include lack of device durability, inconsistent dosing, device inconvenience, poor disaggregation, delivery issues separate from propulsion use, high production costs and / or lack of patient compliance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • dry powder inhaler
  • dry powder inhaler
  • dry powder inhaler

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0119] Preparation of a surfactant-free dry powder comprising FDKP unpowder for inhalers: In an exemplary embodiment, a surfactant-free dry powder comprising FDKP microcrystalline particles was prepared. Using a dual-wire fed high shear mixer, feed approximately equal masses of acetic acid solution (Table 1) and FDKP solution (Table 2) maintained at approximately 25 °C ± 5 °C through a 0.001-in2 orifice at 2000 psi to A precipitate is formed by homogenization. The precipitate was collected in deionized (DI) water of approximately equal temperature. The weight percent content of FDKP crystallites in the suspension is about 2-3.5%. The FDKP concentration of the suspension can be analyzed by drying method for solids content. The FDKP microcrystalline suspension can optionally be washed by tangential flow filtration using deionized water. FDKP crystallites can optionally be isolated by filtration, concentration, spray drying or lyophilization.

[0120] Table 1 Composition of F...

example 2

[0129] Preparation of dry powders including microcrystalline FDKP particles containing epinephrine. To the FDKP microcrystalline suspension obtained as described in Example 1 was added approximately 5% by weight of epinephrine in approximately 5% aqueous acetic acid. Optionally, leucine was also added to the FDKP microcrystalline suspension. The mixture was spray dried using a Buchi B290 spray dryer equipped with a high efficiency cyclone. Nitrogen was used as process gas (60mm). The mixture was dried using 10%-20% pump flow, 90%-100% suction speed and inlet temperature of 170-190°C. The weight percent concentrations of epinephrine and leucine in the resulting powder were 2%-30% and 0%-20%, respectively. The delivery efficiencies of these powders after expulsion from the dry powder inhaler ranged from approximately 50% to 80%.

example 3

[0131] Preparation of dry powders including microcrystalline FDKP particles containing palonosetron. To the FDKP microcrystalline suspension obtained as described in Example 1 was added approximately 5% by weight of a solution of palonosetron hydrochloride in DI. Optionally, a solution of leucine and methionine in deionized water (DI). The mixture was titrated to pH 6.5±0.5 with ammonium hydroxide. The mixture was spray dried using a Buchi B290 spray dryer equipped with a high efficiency cyclone. Nitrogen was used as process gas (60mm). The mixture was dried using 10%-12% pump flow, 90%-100% suction speed and inlet temperature of 170-190°C. The weight percent concentrations of palonosetron, leucine, and methionine in the resulting powder were 5%, 0%-20%, and 0%-10%, respectively. The delivery efficiencies of these powders after expulsion from the dry powder inhaler ranged from approximately 50% to 70%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

A dry powder inhaler is disclosed that includes a replaceable cartridge containing a dry powder for local or systemic delivery through the pulmonary airways and lungs. The inhaler is used with an inhalable dry powder containing a pharmaceutical formulation, including for local or systemic delivery and for the treatment of diseases (such as pulmonary hypertension, cardiovascular disease, allergies, diabetes, obesity, cancer and other diseases) or Active agents or active ingredients for symptoms associated with these or other disorders, such as nausea, vomiting, pain and inflammation.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] Pursuant to 35 U.S.C. §119(e), this application claims the benefit of US Provisional Patent Application No. 62 / 289,095, filed January 29, 2016, the contents of which are incorporated herein by reference in their entirety. technical field [0003] The present disclosure relates to dry powder inhalers having replaceable cartridges comprising dry powders for local or systemic delivery of an active ingredient to and / or through the lungs. The inhaler is used with inhalable dry powders that contain primarily pharmaceutical preparations for the treatment of diseases (such as pulmonary hypertension, cardiovascular disease, diabetes, obesity, and cancer) or symptoms associated with these or other diseases (such as nausea, vomiting, pain and inflammation) active agents or active ingredients. [0004] All references cited in this specification, as well as references to those references, are hereby incorporated by reference in thei...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/00A61M15/00
CPCA61M15/0091A61M15/0045A61M15/0021A61K31/495A61K31/192A61K36/60A61K9/0075A61P11/00A61P9/12A61M2205/583A61M2202/064A61K2300/00A61M15/0028A61K31/137A61K31/473A61K31/5575A61M2206/14A61K31/352A61K31/661A61K9/1617A61M15/0025A61M2205/10A61M2205/121A61M2205/128A61M2207/00
Inventor P·斯般瑟儿·堪赛布伦丹·劳伦奇查得·C·斯穆尼班诺特·阿达莫约瑟夫·瓜内里
Owner MANNKIND CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com